La cadena de opciones muestra datos clave de las opciones de acciones de Reviva Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Reviva Pharmaceuticals..

Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa, Cadena de Opciones

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

The U.S. government's bold move to establish Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as an official reserve asset through President Donald Trump's strategic Bitcoin reserve (SBR) has thrust cryptocurrencies into the spotlight, yet stablecoins like PayPal's PYUSD <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44252537/xrps-rlusd-stablecoin-has-only-0-7-market-share-what-is-going-on">and Ripple's RLUSD</a> are faltering in their bid for market share against offshore giants like Tether's USDT.
What Happened: Signed into effect on March 6, the executive order designates Bitcoin as a sovereign-grade store of value, backed by roughly 100,000 BTC from forfeited Treasury holdings, while a favorable regulatory climate has failed to ignite adoption of U.S.-based stablecoins.
Analysts point to a paradox: despite unprecedented federal endorsement of digital assets, entrenched transnational players continue to overshadow domestic efforts in the stablecoin arena.
The SBR, detailed in H.C. Wainwright &amp; Co. reports, marks a seismic shift for Bitcoin, which dropped more than 15% to below $80,000 amid investor frustration over vague acquisition plans beyond the initial reserve. 
"The EO states that these coins ‘shall not be sold,'" notes the March 11 report, signaling a long-term U.S. commitment to holding its 198,000 BTC—net of 95,000 owed to Bitfinex—far surpassing Germany's recent 50,000 BTC sale.
Meanwhile, a separate U.S. Digital Asset Stockpile, including 61,000 ETH, points toward Bitcoin's elevated status, as the order prohibits proactive altcoin purchases. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44252537/xrps-rlusd-stablecoin-has-only-0-7-market-share-what-is-going-on">XRP&#8217;s RLUSD Stablecoin Has Only 0.7% Market Share: What Is Going On?</a>
This federal backing, paired with Texas's SB-21 allowing state Bitcoin investments, has analysts predicting a global rush to secure Bitcoin, yet stablecoins tell a different story.
Stablecoins, pegged to the dollar and designed for stability, have enjoyed a Donald Trump administration tailwind, with a supportive Securities and Exchange Commission, a Tether-friendly Commerce Secretary, and relaxed banking rules from the Office of the Comptroller of the Currency. 
Paypal&#8217;s PYUSD and Ripple&#8217;s RLUSD—launched in December as an "enterprise-ready" option on the XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) Ledger—have barely scratched the surface of their target markets.
RLUSD holds less than 0.7% of the stablecoin sector nearly three months post-launch, despite stabilizing at its $1 peg after early volatility. 
PayPal's offering, integrated across its apps and third-party platforms, has similarly struggled, with market forces favoring established players like USDT, USDS and USDE.
"The explicit differentiation firmly elevates Bitcoin above other cryptocurrencies," the March 10 H.C. Wainwright report states, highlighting a policy focus that prioritizes Bitcoin's scarcity and value over stablecoins' transactional utility. 
Tether's dominance persists, bolstered by its offshore roots and widespread use, while U.S.-based contenders grapple with adoption hurdles despite regulatory green lights. 
PayPal has stated it remains committed to PYUSD, dismissing concerns tied to a Biden-era subpoena, and Ripple banks on RLUSD's enterprise appeal, but analysts see little dent in the offshore lead.
What&#8217;s Next: The contrast is stark: Bitcoin's reserve status tightens its supply and boosts institutional credibility, while stablecoins—touted as the future of payments—lag, revealing a market resistant to new entrants even under optimal conditions.
As the U.S. positions itself as a crypto leader, the stablecoin struggle point out to Tether's enduring grip.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44244951/bitcoins-heading-to-73000-without-a-fresh-narrative-10x-research">Bitcoin&#8217;s Heading To $73,000 Without A Fresh Narrative: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$PYUSD

$RLUSD

$USDT

$XRP

Bitcoin Reserve Upgrades Crypto But Paypal, Ripple Stablecoins Lag Behind

WIIM

TSLA

Tesla shares are trading higher, rebounding after falling on Monday.

Macro Economic Events

Global

Economics

U.S. State Dept Says Both Delegations Agreed To Name Their Negotiating Teams And Immediately Begin Negotiations Toward An Enduring Peace That Provides For Ukraine's Long-Term Security

LULU

ULTA

Shares of retail and apparel stocks are trading lower following weak guidance from Kohl's, which added to recent consumer concerns.

U.S. State Dept, On Jeddah Meeting Says The U.S. And Ukraine Took Important Steps Toward Restoring Durable Peace For Ukraine; Ukraine Expressed Readiness To Accept The U.S. Proposal To Enact An Immediate, Interim 30-Day Ceasefire; Says The U.S. Will Immediately Lift The Pause On Intelligence Sharing And Resume Security Assistance To Ukraine; U.S.-Ukraine Agreed To Conclude As Soon As Possible A Comprehensive Agreement For Developing Ukraine's Critical Mineral Resources

AMRC, BLD, CISS, CLWT, EFX, FGI, FLNC, KITT, MT, PKX, RIO, RUN, SID, SWK

AMRC

CISS

CLWT

FLNC

KITT

Shares of several companies in the broader industrials space are trading lower amid overall market weakness and tariff concerns.

Throughout the last three months, 4 analysts have evaluated Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $48.5, a high estimate of $55.00, and a low estimate of $44.00. Observing a 17.58% increase, the current average has risen from the previous average price target of $41.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1741716079_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Kodiak Gas Services's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Douglas Irwin</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kodiak Gas Services. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kodiak Gas Services compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Kodiak Gas Services's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Kodiak Gas Services's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KGS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kodiak Gas Services analyst ratings.</a>
<h2>All You Need to Know About Kodiak Gas Services</h2>
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to primarily fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
<h3>Financial Milestones: Kodiak Gas Services's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Kodiak Gas Services showcased positive performance, achieving a revenue growth rate of 36.97% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: Kodiak Gas Services's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 6.17%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kodiak Gas Services's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.46%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.43%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.95.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Kodiak Gas Services: Insights From 4 Financial Analysts

In the preceding three months, 4 analysts have released ratings for Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Genmab, revealing an average target of $43.0, a high estimate of $50.00, and a low estimate of $27.00. This current average represents a 14.0% decrease from the previous average price target of $50.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741716065_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Genmab among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jonathan Chang</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Genmab. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Genmab compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Genmab's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Genmab's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GMAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Genmab analyst ratings.</a>
<h2>About Genmab</h2>
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson &amp; Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson &amp; Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
<h3>Breaking Down Genmab's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Genmab's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 35.34%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Genmab's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 59.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Genmab's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Genmab's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.0% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GMAB

Breaking Down Genmab: 4 Analysts Share Their Views

In the latest quarter, 6 analysts provided ratings for Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Vail Resorts and provided 12-month price targets. The average target is $179.17, accompanied by a high estimate of $215.00 and a low estimate of $152.00. This current average has decreased by 4.7% from the previous average price target of $188.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741716053_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Vail Resorts among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$215.00</td>
<td>$227.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$167.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$178.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$152.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$166.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$197.00</td>
<td>$197.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vail Resorts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vail Resorts compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Vail Resorts's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vail Resorts's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MTN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vail Resorts analyst ratings.</a>
<h2>All You Need to Know About Vail Resorts</h2>
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
<h3>Financial Insights: Vail Resorts</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Vail Resorts's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.66% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Vail Resorts's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -66.41%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -29.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Vail Resorts's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.05%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Vail Resorts's debt-to-equity ratio surpasses industry norms, standing at 6.83. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Vail Resorts Stock

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $341.93, with a high estimate of $500.00 and a low estimate of $280.00. Marking an increase of 4.14%, the current average surpasses the previous average price target of $328.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1741716039_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$284.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Alnylam Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Alnylam Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Breaking Down Alnylam Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Alnylam Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 34.9%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -14.12%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -168.47%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.98%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 19.32. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews

Looking into the current session, Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) shares are trading at $331.17, after a 3.02% decrease. Over the past month, the stock decreased by 5.56%, but over the past year, it actually increased by 16.16%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1741716027_0.png" alt="Past Year Chart" />

<h3>Comparing Visa P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 101.89 in the Financial Services industry, Visa Inc. has a lower P/E ratio of 34.42. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1741716027_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Visa

In the last three months, 7 analysts have published ratings on CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CarMax, revealing an average target of $92.43, a high estimate of $105.00, and a low estimate of $72.00. Witnessing a positive shift, the current average has risen by 6.41% from the previous average price target of $86.86.
<img src="https://www.benzinga.com/files/images/story/2025/1741716027_0_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of CarMax's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$72.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$88.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CarMax. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CarMax compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CarMax's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into CarMax's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KMX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CarMax analyst ratings.</a>
<h2>Unveiling the Story Behind CarMax</h2>
CarMax sells, finances, and services used and new cars through a chain of around 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue (79% in fiscal 2024 due to the chip shortage) and wholesale about 13% (19% in fiscal 2024), with the remaining portion composed of extended service plans and repair. In fiscal 2024, the company retailed and wholesaled 765,572, and 546,331 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in 2023. It seeks over 5% share a few years from now. CarMax is based in Richmond, Virginia.
<h3>CarMax's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: CarMax's remarkable performance in 3 months is evident. As of 30 November, 2024, the company achieved an impressive revenue growth rate of 1.22%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: CarMax's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.02%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CarMax's ROA stands out, surpassing industry averages. With an impressive ROA of 0.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 3.09.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Assess CarMax: What You Need To Know

During the last three months, 4 analysts shared their evaluations of Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Crane, revealing an average target of $181.75, a high estimate of $200.00, and a low estimate of $157.00. This upward trend is evident, with the current average reflecting a 1.96% increase from the previous average price target of $178.25.
<img src="https://www.benzinga.com/files/images/story/2025/1741716019_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Crane among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$170.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$152.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Crane. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crane compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Crane's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Crane's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Crane analyst ratings.</a>
<h2>Delving into Crane's Background</h2>
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
<h3>Unraveling the Financial Story of Crane</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Crane's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.57% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Crane's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Crane's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 5.04%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Crane's ROA excels beyond industry benchmarks, reaching 3.06%. This signifies efficient management of assets and strong financial health.
Debt Management: Crane's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Crane Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Asana Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) stock plunged after multiple Wall Street firms cut their respective price targets.
Asana reported <a target="_blank" href="https://www.benzinga.com/25/03/44254322/asana-shares-are-tumbling-tuesday-whats-driving-the-action" rel="noreferrer noopener">fourth-quarter revenue</a> of $188.33 million, beating analyst estimates of $188.1 million. The company reported breakeven fourth-quarter earnings, beating analyst estimates for a loss of 1 cent per share.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44245291/ciena-q1-earnings-revenue-and-eps-beat-estimates-ceo-eyes-ai-cloud-network-tailwinds" rel="noreferrer noopener">Ciena Q1 Earnings: Revenue and EPS Beat Estimates, CEO Eyes AI, Cloud Network Tailwinds</a>
Asana guided for first-quarter revenue of $184.5 million-$186.5 million and first-quarter adjusted EPS of $0.02.
Asana co-founder, CEO, and chair&nbsp;Dustin Moskovitz&nbsp;informed the board of his intention to transition to chair. Asana has retained an executive search firm to search for a new CEO.
JP Morgan analyst Pinjalim Bora maintained Asana with an Underweight rating and lowered the <a target="_blank" href="https://www.benzinga.com/quote/ASAN/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$15&nbsp;to&nbsp;$13</a>.
The analyst writes that Asana&#8217;s fourth quarter highlighted the stabilization of growth and retention metrics while profitability outperformed. The fourth-quarter revenue aligned with consensus and marked a steady growth versus last quarter on an FX-adjusted basis.
Calculated billings landed slightly above, accelerating into the low-double-digit zone. Dollar-based net retention rate (DBNRR) was stable at 96% on a reported basis, while the in-quarter net retention rate improved sequentially.
While non-tech verticals were stable, Asana highlighted continued softness in the tech vertical (primarily driven by a reduction in seats and one logo churn).
This pressured the reported DBNRR for customers spending over $100K in ACV, which contracted 3 pts sequentially to 96%, landing in line with the overall reported number for the first time.
On AI studio, Asana reported that the early momentum had exceeded the company&#8217;s expectations. It has already amassed a multi-million dollar pipeline and paid customers.
As such, the company aims to establish a dedicated sales team to capitalize on the opportunity and embark on some broader sales capacity alignment.
The brightest spot in the results was a solid improvement in profitability in the quarter and in the guide.
While the company highlighted several avenues of conservatism in the guide (not baking in any improvement in net retention or performance of the tech vertical and baking in de minimis contribution from AI Studio, with no contribution from consumption), Bora&#8217;s understanding is that the guide was set a couple of weeks ago, and does not bake in any deterioration in macro from the current levels, which could be a risk to the plan (offset by potential improvement in FX during that period).
Overall, while growth continues to materially lag that of peers, which would likely drive underperformance in the shares in the near term. Bora noted Asana as essentially a profitability story from here on out, with multiple levers to drive material improvement in margins in the future.
Bora projected first-quarter revenue of $186 million and adjusted EPS of $0.02.
Price Action: ASAN stock is down 23.6% at $12.74 at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44235249/slowdown-and-tariff-talk-grips-the-hottest-sector-on-wall-street-semiconductor-etf-now-has-a-negative-1-year-return" target="_blank" rel="noreferrer noopener">Slowdown And Tariff Talk Grips The Hottest Sector On Wall Street &#8211; Semiconductor ETF Now Has A Negative 1-Year Return</a></li>
</ul>
Photo by FellowNeko via Shutterstock

Analyst Color

Price Target

Reiteration

Movers

Trading Ideas

ASAN

Asana Growth Materially Lags Peers, JP Morgan Cuts Price Forecast

LAMR

Shares of real estate ETFs are trading lower following a rise in treasury yields, which can raise borrowing costs for firms and enhance the relative attractiveness of bonds for income-oriented investors.

Lake Street initiates coverage on Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) with a Buy rating and announces Price Target of $30.

Initiation

LAKE

Lake Street Initiates Coverage On Lakeland Industries with Buy Rating, Announces Price Target of $30

Biotech

General

MRNA

Moderna Exec Says Co Expects "Little Bit More Of A Business As Usual" In Terms Of Vaccine-Related Meetings As Confirmations For Key Healthcare Roles Take Place

Wall Street's losing streak extended into Tuesday, with stocks deepening their slump as continued trade war fears rattled investor sentiment. 
The Nasdaq 100 slipped 0.6% by midday trading in New York after suffering on Monday its worst single-day drop since September 2022<a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44255030/nasdaq-100-trades-below-its-200-day-moving-average-history-says-you-should-buy-the-dip-now"> in the prior session. </a>
The broader S&amp;P 500 slid to a seven-month low, amplifying concerns over the market's near-term trajectory.
The proportion of S&amp;P 500 stocks trading above their 200-day moving average has now shrunk to 44%, the lowest since November 2023. Each sector traded in the red, highlighting broad-based market weakness. 
The Dow Jones Industrial Average was the biggest underperformer on Tuesday, with industrial stocks bearing the brunt of escalating trade tensions.
On Tuesday, President Donald Trump escalated trade tensions by raising tariffs on Canadian steel and aluminum imports to 50%, responding to Ontario's move to levy a 25% tariff on <a href="https://www.benzinga.com/news/25/03/44253100/trump-slaps-50-tariff-on-canadian-steel-aluminum-threatens-auto-industry">electricity exports to the U.S. </a>
In a Truth Social post, Trump announced he had instructed the Commerce secretary to enforce the additional 25% tariff, which will take effect Wednesday morning.
On the macroeconomic front, job openings in the U.S. showed unexpected resilience, rising by 232,000 to 7.74 million in January from a downwardly revised 7.51 million in December. The reading exceeded market forecasts of 7.63 million, suggesting positive labor market news despite broader economic jitters.
The U.S. dollar continued its descent, with the dollar index slipping to six-month lows. Treasury yields edged higher ahead of Wednesday's closely watched inflation report for February, signaling that investors were not rushing into safe-haven bonds despite the ongoing market turbulence.
Commodities, meanwhile, found favor as investors sought inflation hedges. Gold advanced 1%, silver surged 2.3% and copper climbed 3%, reflecting renewed demand for tangible assets in a climate of heightened financial instability.
Bitcoin endured a wild session, initially plunging to an intraday low of $76,600 — its lowest level since Nov. 10, 2024 — before rebounding to post a 3.9% gain on the day.
<h1 class="wp-block-heading">Wednesday's Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,011.25</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,305.23</td>
<td>-0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,552.25</td>
<td>-1.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,296.00</td>
<td>-1.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;fell 1.2% to $553.88.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 1.5% to $413.04.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.6% to $469.56.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.7% to $199.32.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) managed to contain losses, yet still down 0.9%; the&nbsp;Communication Services&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)&nbsp;was the worst sector performer, down 1.9%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) fell 3.3% after missing both <a href="https://www.benzinga.com/news/earnings/earnings-misses/25/03/44255998/oracles-q3-falls-short-but-ai-demand-keep-long-term-outlook-strong-say-analysts">earnings and revenue estimates last quarter</a>.</li>
<li>Other stocks reacting to corporate earnings report included: Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>)​, down 4.7%; Viking Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>)​, <a href="https://www.benzinga.com/news/earnings/25/03/44254442/viking-holdings-beats-on-q4-earnings-says-88-passenger-cruise-days-for-fy25-already-booked">down </a>6.4%; DICK&#8216;S Sporting Goods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>)​, down 5.8% and Ciena Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>)​, down 3.6%,</li>
<li>Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) shares dropped 6.9% after the company acknowledged at a conference that the quarter has been &#8220;challenging from a competitive intensity standpoint.&#8221; Verizon expects first-quarter postpaid phone gross additions to remain flat or decline slightly compared<a href="https://www.benzinga.com/news/guidance/25/03/44250482/verizon-communications-stock-is-sliding-tuesday-heres-why"> to the same period last year</a>.</li>
<li>Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) <a href="https://www.benzinga.com/general/travel/25/03/44237055/delta-air-lines-cuts-q1-guidance-below-estimates-airline-stocks-fall">revised its first-quarter earnings-per-share guidance</a> downward to 30 cents to 50 cents from the previous 70 cents–$1 range. The airline also lowered its revenue growth forecast to 3%–4% from the earlier 7%–9% projection. Delta shares fell 8.5%.</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44255030/nasdaq-100-trades-below-its-200-day-moving-average-history-says-you-should-buy-the-dip-now">Nasdaq 100 Trades Below Its 200-Day Moving Average: History Says You Should Buy The Dip Now</a></li>
</ul>
Photo: Shutterstock

Equities

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

CIEN

SPDR Dow Jones Industrial Average ETF Trust

FERG

ORCL

Wall Street Drop Deepens As Trade War Fears Escalate, S&P 500 Hits 7-Month Lows: What's Driving Markets Tuesday?

Keefe, Bruyette &amp; Woods analyst Jade J. Rahmani downgraded Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from Outperform to Market Perform and reduced <a target="_blank" href="https://www.benzinga.com/quote/LEN/analyst-ratings" rel="noreferrer noopener">the price forecast from $152 to $141.</a>
The analyst writes that the company&#8217;s valuation is now comparable to large-cap peers, with potential downside risks to estimates.
The analyst expects a challenging Spring selling season and growing risks to gross margin due to the tough macro environment and uncertainty <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43625476/lennar-completes-spin-off-of-millrose-properties" rel="noreferrer noopener">from the </a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43625476/lennar-completes-spin-off-of-millrose-properties" rel="noreferrer noopener">Millrose Properties</a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43625476/lennar-completes-spin-off-of-millrose-properties" rel="noreferrer noopener"> spin-off</a>.
Consequently, Rahmani stated that he had adopted a more cautious approach towards the company. The analyst moves to the sidelines and awaits a better entry point.
While the analyst still sees the company as well-positioned due to several factors, such as its low financial leverage, potential ROE upside from the Millrose spin-off, and capital efficiency initiatives, the current housing market presents significant challenges.
The analyst cut the 2025-2026 estimates by 3%-4% to $11.89 and $13.44.
Rahmani continues to see order growth of 3% &#8211; 7% for the period. Meanwhile, the analyst revised estimates for deliveries growth to 5% &#8211; 6% (vs. prior estimates of 5% &#8211; 7%), gross margin to be 20.0% &#8211; 20.3% (vs. 20.3% &#8211; 20.5% earlier), and SG&amp;A to 7.6% &#8211; 7.7% (vs. 7.6% prior).
Investors can gain exposure to the stock via&nbsp;iShares U.S. Home Construction ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITB#BATS">ITB</a>) and John Hancock Exchange-Traded Fund Trust John Hancock Fundamental All Cap Core ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHAC#NYSE">JHAC</a>).
Price Action: LEN shares are down 3.12% at $121.32 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44200622/lennar-kb-home-face-tougher-housing-market-goldman-sachs-cuts-forecast-amid-slowing-demand" target="_blank" rel="noreferrer noopener">Lennar &amp; KB Home Face Tougher Housing Market, Goldman Sachs Cuts Forecast Amid Slowing Demand</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Downgrades

iShares Dow Jones US Homenstruction Index Fund

JHAC

Lenna Analyst Moves To Sidelines, Downgrades Stock And Awaits Better Entry Point

Mizuho analyst Ben Chaiken maintains Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Outperform and lowers the price target from $227 to $215.

Mizuho Maintains Outperform on Vail Resorts, Lowers Price Target to $215

Press Releases

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Earnings

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Health Care

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

IPOs

Reviva Announces Proposed Public Offering

Financing

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

Management

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Comments

Reviva Pharmaceuticals

Reviva Pharmaceuticals (RVPH) Opciones

Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL